Total Raised

$247.65M

Investors Count

19

Deal Terms

4

Investments

2

Shukun Technology Funding, Shukun Technology Valuation & Shukun Technology Revenue

6 Fundings

Shukun Technology's latest funding round was a Series D for $108.09M on August 16, 2021.

Shukun Technology's valuation in December 2020 was $600M.

Shukun Technology's latest post-money valuation is from August 2021.

Sign up for a free trial to see Shukun Technology's valuations in August 2021, August 2020, June 2020 and more.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

8/16/2021

Series D

$108.09M

$99M

0

FY undefined

6

12/28/2020

Series C

$99M

$600M

0

FY undefined

10

8/31/2020

Series B - III

$99M

$99M

0

FY undefined

10

6/15/2020

Series B - II

$99M

$99M

0

FY undefined

10

2/18/2019

Series B

$99M

0

FY undefined

10

Date

8/16/2021

12/28/2020

8/31/2020

6/15/2020

2/18/2019

Round

Series D

Series C

Series B - III

Series B - II

Series B

Amount

$108.09M

$99M

$99M

$99M

$99M

Investors

Valuation

$99M

$600M

$99M

$99M

Revenue

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

Sources

6

10

10

10

10

Shukun Technology Deal Terms

4 Deal Terms

Shukun Technology's deal structure is available for 4 funding rounds, including their Series D from August 16, 2021.

Round

Series D

Series C

Series B - III

Series B - II

Funding Date

$99M

$99M

$99M

$99M

Pre-Money Valuation

$99M

$99M

$99M

$99M

Post-Money Valuation

$99M

$99M

$99M

$99M

Amount Raised

$99M

$99M

$99M

$99M

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

$99M

$99M

$99M

$99M

Board Voting

$99M

$99M

$99M

$99M

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Series D

$99M

$99M

$99M

$99M

$99M

$99M

Series C

$99M

$99M

$99M

$99M

$99M

$99M

Series B - III

$99M

$99M

$99M

$99M

$99M

$99M

Series B - II

$99M

$99M

$99M

$99M

$99M

$99M

Shukun Technology Investors

19 Investors

Shukun Technology has 19 investors. Marathon Venture Partners invested in Shukun Technology's Series D funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

7/3/2018

8/16/2021

4
Series A, Series B (2019), Series C (2020), Series D (2021)

Venture Capital

China

12/28/2020

8/16/2021

2
Series C, Series D (2021)

Venture Capital

China

8/16/2021

8/16/2021

1
Series D

Private Equity

China

00/00/0000

00/00/0000

Primavera Capital Group

Subscribe to see more

Private Equity

China

00/00/0000

00/00/0000

Jane Street Group

Subscribe to see more

Corporation

New York

First funding

7/3/2018

12/28/2020

8/16/2021

00/00/0000

00/00/0000

Last Funding

8/16/2021

8/16/2021

8/16/2021

00/00/0000

00/00/0000

Investor

Primavera Capital Group

Jane Street Group

Rounds

4
Series A, Series B (2019), Series C (2020), Series D (2021)
2
Series C, Series D (2021)
1
Series D

Subscribe to see more

Subscribe to see more

Board Seats

Type

Venture Capital

Venture Capital

Private Equity

Private Equity

Corporation

Location

China

China

China

China

New York

Shukun Technology Investments

2 Investments

Shukun Technology has made 2 investments. Their latest investment was in CureFun as part of their Seed VC - III on April 4, 2022.

CBI Logo

Shukun Technology Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

4/8/2022

Seed VC - III

CureFun

Yes

1

1/25/2022

Series A

Subscribe to see more

Subscribe to see more

10

Date

4/8/2022

1/25/2022

Round

Seed VC - III

Series A

Company

CureFun

Subscribe to see more

Amount

New?

Yes

Subscribe to see more

Co-Investors

Sources

1

10

You May Also Like

A
Aidoc Medical

Aidoc finds and flags critical findings in medical images. By automatically prioritizing urgent, life-threatening conditions like intracranial hemorrhage and pulmonary embolism, Aidoc saves lives, improves patient care and cuts waiting time for the must urgent patients down to only a few minutes. The always-on AI integrates into a radiologist's workflow, reprioritizing cases without forcing radiologists to change the way they work. Aidoc was founded in 2016 and is based in Tel Aviv, Israel.

Ultromics Logo
Ultromics

Ultromics is a global health technology company that provides autonomous echocardiography analysis through AI solutions – empowering physicians to make fast, accurate decisions when diagnosing cardiovascular disease. Its cloud-based service, EchoGo, uses artificial intelligence to fully automate the pathway to diagnosis, providing near-instant reports for clinicians without any need for physical software on site.

R
RadNet

RadNet is a national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. The company has a network of 293 owned and/or operated outpatient imaging centers.

QUIBIM Logo
QUIBIM

Quibim, a company with its headquarters in Valencia, Spain, provides a whole-body medical imaging analysis. Quibim products are used worldwide by a huge diversity of research and care teams. Partners use Quibim Precision, a CE-marked whole-body imaging ecosystem, for a wide range of applications from detecting a disease to tracking the efficacy of treatments. Quibim follows an AI-first approach to help detect pathologies across every body part and imaging modality, using quantitative imaging biomarkers.

Ibex Medical Analytics Logo
Ibex Medical Analytics

Ibex Medical Analytics develops AI-driven clinical decision support tools that help pathologists deliver more efficient, metric-driven, objective and accurate diagnosis. Ibex develops a diagnostic system that uses computer vision, machine learning, and electronic medical records to confirm cancer diagnoses of tissue biopsies. The company was founded in 2016 and is based in Israel.

Infervision Logo
Infervision

Infervision is a global high-tech enterprise in medical artificial intelligence, aiming to empower doctors with higher efficiency and benefit patients with better diagnosis, outcome, and lower cost. Infervision provides products and services to providers, and patients; with robust A.I. solutions fully integrated with the healthcare workflow to help diagnosing various diseases and conditions such as cerebral hemorrhage, lung cancer, bone fractures, emphysema, and more. Infervision also provides an AI-powered research platform for medical professionals with any research directions and needs.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.